ArticleWorld journal of gastrointestinal oncology2025
Folate receptor-positive circulating tumor cells might function as potential biomarkers for hepatocellular carcinoma.
Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Predictive model based on folate receptor-positive circulating tumor cells in neoadjuvant immunochemotherapy for esophageal cancer.Journal of gastrointestinal oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly metastasis and recurrence are risk factors that negatively affect the prognosis of advanced hepatocellular carcinoma (HCC). Alpha fetoprotein (AFP) is currently the most prevalent serum biomarker for detecting HCC and predicting tumor recurrence. However, its sensitivity and specificity are not sufficient, especially in patients who are AFP negative.
aimTo detect folate receptor (FR)-positive circulating tumor cells (CTCs) and explore their role in the diagnosis and staging of HCC.
methodsThis work is a retrospective study that included 128 consecutive patients with benign or malignant disease of the liver from 2020 to 2021. FR + CTCs were collected from 3 mL of peripheral blood
resultsThe FR + CTCs counts showed excellent diagnostic efficacy in patients with HCC, with high sensitivity (0.905) and specificity (0.773) compared with patients with benign disease. Compared with that of the AFP level, the area under the receiver operating characteristic curve of the FR + CTC count is significantly greater (0.900 compared with 0.730,
conclusionLigand-target polymerase chain reaction is a sensitive tool for quantifying the number of FR + CTCs in HCC patients. These findings could provide new insight for stratifying HCC patients and predicting the recurrence of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.